SYDNEY--2 Mar--AsiaNet/InfoQuest
DIABETES PATIENTS...
SYDNEY: Fenofibrate treatment reduces cardiovascular disease (CVD) risk
(defined by total cardiovascular events: the composite of cardiovascular death,
myocardial infarction, stroke, and coronary and carotid revascularization) in
patients with type 2 diabetes and atherogenic dyslipidemia, that is, the
combination of high triglyceride (2.3 mmol/L-200mg/dL or higher) and low
high-density lipoprotein (HDL) cholesterol (